metrology of bioactive molecule and target discovery

治疗患有慢性疼痛导致功能障碍的人类和动物患者是一个严重的未得到满足的医疗需求。动物健康、福利和疼痛管理是我们兽医使命的核心。开发疼痛管理的新疗法是一个挑战，因为它需要使用实验动物模型，在那里我们可以诱导疼痛。有许多限制，包括伦理考虑、技术挑战和成本。因此，当务之急是开发新的战略，导致我们如何开发新的治疗方法来缓解疼痛的范式转变。用于精确治疗的分子指纹是精确医学的核心。这一新的范例与“一刀切”的传统方法背道而驰，并优先考虑患者的特征(即分子和表型)。具体地说，使用特征化患者的蛋白质组技术的全面分子图谱可以用于开发有针对性的和更特异的止痛疗法，以改善兽医患者的临床结果，并改善止痛药向临床的转化。这是一个在知识上取得显著进步的巨大机会，因为对动物进行的自然发生疾病研究对其他动物物种和人类具有更大的翻译价值。加拿大生物活性分子计量学研究主席和靶标发现任务将有条不紊地表征患有慢性疼痛的兽医患者的分子特征，并确定新的生物活性分子及其靶点，以设计创新的止痛策略，以改善动物福利，并加强止痛药向临床的转化。研究主席将有三个轴心：1)对慢性和炎症性疼痛背后的分子特征进行全面分析；2)开发具有更高检测灵敏度的创新质谱分析策略，以精确研究蛋白质靶标的参与，并确定新的生物活性分子和新靶点；3)开发和验证替代药物和高通量方法，以评估使用秀丽线虫的候选药物的疗效，以实现伦理目标并扩大接受测试的候选药物的数量。我们努力开发创新的解决方案，以解决慢性疼痛药物治疗中未得到满足的需求。

There is a critical unmet medical need to treat human and animal patients suffering from chronic pain leading to functional impairment. Animal health, welfare and pain management is at the heart of our mission in veterinary medicine. Developing new therapeutics for pain management is a challenge because it requires the use of experimental animal models, where we induce pain. There are numerous limitations, including ethical considerations, technical challenges and cost. Therefore, it is imperative to develop new strategies leading to a paradigm shift in how we develop new therapeutics to alleviate pain. Molecular fingerprinting for precision therapies is the heart of precision medicine. This new paradigm is a departure from the "one-size-fits-all" traditional approach and prioritizes patient characteristics (i.e. molecular and phenotypic). Specifically, a comprehensive molecular profiling using proteomic technologies of characterized patients can be used to develop targeted and more specific pain therapies to improve clinical outcomes in veterinary patients and improve the translation of analgesic drugs to the clinic. This is a tremendous opportunity to make remarkable advancements in knowledge, since naturally occurring disease studies in animals have more translational value to other animal species and humans. The Canada research chair in metrology of bioactive molecule and target discovery mission will be to methodically characterize the molecular signature of veterinary patients suffering from chronic pain and identify new bioactive molecules and their targets to design innovative pain relief strategies to improve animal welfare and strengthen the translation of analgesic drugs to the clinic. The Research Chair will have three axes: 1) Perform comprehensive characterizations of the molecular signatures that underlie chronic and inflammatory pain; 2) Develop innovative mass spectrometry analytical strategies with increased detection sensitivity to precisely study protein target engagement and identify new bioactive molecules and new targets; 3) Develop and validate alternatives and high-throughput methods to evaluate the efficacy of drug candidates using Caenorhabditis elegans to meet ethical objectives and broaden the number of candidates tested. We strive to develop innovative solutions to resolve unmet needs in the drug treatment of chronic pain.